| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Observational Study |
| Article Title |
Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Marta Maia Bosca-Watts, Xavier Cortes, Marisa Iborra, Jose Maria Huguet, Laura Sempere, Gloria Garcia, Rafa Gil, MariFe Garcia, Marga Muñoz, Pedro Almela, Nuria Maroto and Jose Maria Paredes |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Marta Maia Bosca-Watts, PhD, MD, Inflammatory Bowel Disease Unit, Digestive Disease Department, University of Valencia, University Clinic Hospital of Valencia, Avda. Blasco Ibañez 17, 46010 Valencia,
Spain. inflamatoriahcuv@gmail.com
|
| Key Words |
Golimumab; Ulcerative colitis; Real-life results |
| Core Tip |
Golimumab is a fully humanized anti-tumor necrosis factor-alpha (anti-TNF) monoclonal antibody, which has recently been accepted in clinical practice. Pivotal studies have demonstrated the drug’s benefits, but real-life studies are still scarce. This observational, prospective and multi-center study in moderate-severe ulcerative colitis patients, confirmed golimumab’s short-term (14 wk) effectiveness. A high percentage of patients had responded and were off steroids at the end of follow-up. No severe adverse events were observed. Intensification (reducing the drug administration interval or increasing the dosage) may be useful in many slow-to-respond cases. |
| Publish Date |
2016-12-19 20:29 |
| Citation |
Bosca-Watts MM, Cortes X, Iborra M, Huguet JM, Sempere L, Garcia G, Gil R, Garcia M, Muñoz M, Almela P, Maroto N, Paredes JM. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study. World J Gastroenterol 2016; 22(47): 10432-10439 |
| URL |
http://www.wjgnet.com/1007-9327/full/v22/i47/10432.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v22.i47.10432 |
